Anthrocell’s current product offering consists of its proprietary AnthroCell® platform for the production of biobetters, as well as a growing range of biobetters based on this platform.

To broaden its product offering, Anthrocell is currently pursuing a comprehensive R & D program to maximise the potential of its technology. The program is currently proceeding along four primary lines of enquiry:

  • Optimisation of serum free media conditions for achieving maximal cell growth and mAb yields.
  • Optimisation of the bioreactor protocol to scale up production for manufacturing.
  • Full cell line characterisation and safety profiling in line with industry best practices and regulatory requirements.
  • Identification of new mAbs with the potential to benefit the greatest number of patients from their production as biobetters based on the AnthroCell® platform.